Drugs for Oncogenic Osteomalacia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 11)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
2 |
|
Immunoglobulins |
|
Phase 4 |
|
|
|
3 |
|
Antibodies |
|
Phase 4 |
|
|
|
4 |
|
Infigratinib |
Approved, Investigational |
Phase 2 |
|
872511-34-7 |
53235510 |
Synonyms:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea
BGJ 398|BGJ-398|BGJ398|NVP-BGJ398|Truseltiq®
BGJ398
|
BGJ-398
INFIGRATINIB
MVP-BGJ398
NVP-BGJ398
|
|
5 |
|
Mitogens |
|
Phase 2 |
|
|
|
6 |
|
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid |
|
Phase 1 |
|
|
|
7 |
|
Chelating Agents |
|
Phase 1 |
|
|
|
8 |
|
Somatostatin |
Approved, Investigational |
Early Phase 1 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
9 |
|
Dimenhydrinate |
Approved |
|
|
523-87-5 |
10660 |
Synonyms:
(O-BENZHYDRYL(DIMETHYLAMINO)ETHANOL) 8-CHLOROTHEOPHYLLINATE
1)
8-CHLORO-1,3-DIMETHYL-3,7-DIHYDRO-1H-PURINE-2,6-DIONE - 2-(DIPHENYLMETHOXY)-N,N-DIMETHYLETHANAMINE (1
8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)
ANTEMIN
BENZHYDRYL-BETA-DIMETHYLAMINOETHYLETHER 8-CHLOROTHEOPHYLLINE
Benzhydryl-β-dimethylaminoethylether 8-chlorotheophylline
BETA-DIMETHYLAMINOETHYL BENZHYDRYL ETHER 1,3-DIMETHYL-8-CHLOROXANTHINE
CHLORANAUTINE
DIMENHIDRINATO
DIMENHYDRINATE
|
DIMENHYDRINATUM
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINATE
DIPHENHYDRAMINE 8-CHLOROTHEOPHYLLINE
DIPHENHYDRAMINE THEOCLATE
DIPHENHYDRINATE
DRAMAMINE
N,N-DIMETHYL-2-DIPHENYLMETHOXYETHYLAMINE 8-CHLOROTHEOPHYLLINATE
NSC-117855
O-BENZHYDRYLDIMETHYLAMINOETHANOL 8-CHLOROTHEOPHYLLINATE
VERTIGO-VOMEX S
β-dimethylaminoethyl benzhydryl ether 1,3-dimethyl-8-chloroxanthine
|
|
10 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
Early Phase 1 |
|
63-91-2, 673-06-3 |
6140 71567 |
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Β-PHENYL-L-ALANINE
|
|
11 |
|
Fluorodeoxyglucose F18 |
|
|
|
|
|
Interventional clinical trials:
(show all 12)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO) |
Recruiting |
NCT05357573 |
Phase 4 |
KRN23 |
2 |
A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia |
Completed |
NCT02304367 |
Phase 2 |
|
3 |
A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome and a Post-marketing Study of KRN23 Switched From the Phase 2 Trial |
Completed |
NCT02722798 |
Phase 2 |
KRN23 |
4 |
68Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients With Tumor Induced Osteomalacia |
Recruiting |
NCT03736564 |
Phase 1, Phase 2 |
|
5 |
BGJ398 for the Treatment of Tumor-Induced Osteomalacia |
Terminated |
NCT03510455 |
Phase 2 |
BGJ398 |
6 |
Head-to-head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-induced Osteomalacia |
Unknown status |
NCT04689893 |
Phase 1 |
68Ga-Dotatate;68Ga-DOTA-JR11 |
7 |
Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors |
Unknown status |
NCT02331966 |
|
|
8 |
68Ga-DOTATATE PET/CT for Detection and Evaluation of the Causative Tumor of Oncogenic Osteomalacia |
Unknown status |
NCT01524016 |
Early Phase 1 |
68Ga-DOTATATE |
9 |
Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia |
Unknown status |
NCT01660308 |
|
|
10 |
Tumor-induced Osteomalacia Disease Monitoring Program (TIO DMP) |
Recruiting |
NCT04783428 |
|
|
11 |
Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia |
Recruiting |
NCT04045834 |
|
|
12 |
Expanded Access to Burosumab |
Available |
NCT03775187 |
|
|
|